Biotech Business - September 12, 2022
Omnio receives capital injection of 1.5 million EUR
The capital investment from Omnio’s shareholders will be used for ongoing development work and to begin creating a blueprint for manufacturing. The company has already made a number of physician-led studies and successful trials involving patients with clinical wounds, they state in their press release. “It is unbelievable what some people have to go through […]
Acquisition - September 5, 2022
Center for Translational Research acquires Admescope’s Swedish operation
Center for Translational Research AB acquires Admescope’s Swedish operation (changing name to Metasafe) and strengthens collaboration with Admescope and Symeres. Center for Translational Research CTR is a group of complementary life science service companies providing expert services and advice within product development. The services provided by Admescope Sweden/Metasafe complements well the current offerings and will […]
Biotech Business - August 29, 2022
Calliditas receives European Commission approval
Calliditas Therapeutics announced in July that the European Commission (EC) has granted conditional marketing authorization for Kinpeygo for the treatment of primary immunoglobulin A (IgA) nephropathy (IgAN) in adults at risk of rapid disease progression with a urine protein-to-creatinine ratio (UPCR) ≥1.5 g/gram. Kinpeygo is an orphan medicinal product and the first and only approved […]
Biotech Business - August 26, 2022
Mendus announces financing commitments totaling up to 250 MSEK
The company has entered into a binding agreement for a financing commitment with Negma Group (of up to 200 MSEK) as well as a binding commitment letter to receive a shareholder loan (up to 50 MSEK) with its existing shareholder Van Herk Investments. The financing commitments will allow the company to reach its next clinical […]
Biotech Business - August 19, 2022
Nordic Nanovector to explore strategic options
The Board has initiated this review aiming to optimize shareholder value following its recent decision to discontinue the PARADIGME study for Nordic Nanovector’s lead asset Betalutin and implement a restructuring of the company. The company’s Board of Directors has appointed Carnegie Investment Bank to explore strategic options available to the company. “The decision to discontinue […]
Biotech Business - August 19, 2022
Oncopeptides receives European Commission approval
Oncopeptides has announced that the European Commission has granted Pepaxti marketing authorization in combination with dexamethasone. The approval concerns the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, […]
